Clearmind Medicine Inc Ordinary Shares CMND
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.03
- Day Range
- $1.86–2.13
- 52-Week Range
- $1.86–524.00
- Bid/Ask
- $1.98 / $2.01
- Shares Outstanding
- 1.49M
- Market Cap
- $2.96M
- Volume/Avg
- 3,698 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
Valuation
|
Metric
|
CMND
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.23 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CMND
|
|---|---|
Quick Ratio | 4.73 |
Current Ratio | 4.79 |
Interest Coverage | −711.76 |
Quick Ratio
CMND
Profitability
|
Metric
|
CMND
|
|---|---|
Return on Assets (Normalized) | −87.08% |
Return on Equity (Normalized) | −380.90% |
Return on Invested Capital (Normalized) | −138.28% |
Return on Assets
CMND
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|bFKl%@ | LOCK|Z#W? | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Hw!vdw> | LOCK|CDR?V | $70B | |||
| argenx SE ADR
ARGX
| LOCK|FhZ@%R | LOCK|^^K | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|W?%$jG | LOCK|&&PM@ | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<G%Y^m | LOCK|$? | $36B | |||
| Moderna Inc
MRNA
| LOCK|&&B>&X | LOCK|!<$ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%kqR!CgB | LOCK|vyyQ@ | $25B | |||
| Incyte Corp
INCY
| LOCK|<<vr<sC | LOCK|&F | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|&$!Yr$ | LOCK|Q@ | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|St!ZkX | LOCK|G@d | $16B |
United States